Abstract
Abstract Background: ALDH bright cells identify cancer stem cells in breast cancer and other tumors as well. In the past, we were able to generate ALDH1A188-96 peptide specific T cells. Now we hypothesize that ALDH1A188-96 peptide-specific T cells can target cancer stem cells which are otherwise untreatable using available therapies. Methods: ALDH bright cells were identified by FACS analysis and sorted from head and neck and breast cancer cell lines. Those cells were injected in NOD/SCID mice in order to study their tumorigenicity. The reactivity of the ALDH peptide-specific T cells was tested in IFN-g ELISPOT assays. Results: ALDH bright cells were isolated from head and neck and breast cancer cell lines and found highly tumorigenic in NOD/SCID mice. ALDH1A188-96 peptide-specific CD8+ T cells recognized ALDH bright cells in ELISPOT assays but did not recognized ALDH negative cells or the bulk tumor cell lines unless those cells were pulsed with the exogenous ALDH1A188-96 peptide. Conclusion: We are able to target ALDH bright cells for immunotherapy utilizing ALDH1A1 specific T cells and this may result in control of tumor growth and metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
